Cosentyx (secukinumab) is a biologic medication used to treat various autoimmune diseases, including psoriasis and psoriatic arthritis. While it is an effective treatment, patients may wonder if there are any reported birth defects associated with its use.

According to the sources provided, there is limited information on the potential risks of Cosentyx use during pregnancy. The drug is classified as a pregnancy category B medication, which means that animal studies have not shown any adverse effects on the fetus, but there is a lack of data from human studies [1].

A study published in the Journal of Clinical Rheumatology examined the safety of Cosentyx use during pregnancy in patients with psoriatic arthritis. The study found that out of 12 pregnancies exposed to Cosentyx, there were no reports of major birth defects or adverse pregnancy outcomes [2]. However, it is important to note that this was a small study with a limited sample size.

Another study published in the Journal of the European Academy of Dermatology and Venereology looked at the safety of Cosentyx use during pregnancy in patients with psoriasis. The study found that out of 19 pregnancies exposed to Cosentyx, there were no reports of major birth defects or adverse pregnancy outcomes [3]. However, like the previous study, this was also a small study with a limited sample size.

Overall, while there is limited data on the safety of Cosentyx use during pregnancy, the available studies suggest that there may not be an increased risk of birth defects or adverse pregnancy outcomes associated with its use. However, it is important for patients to discuss any potential risks with their healthcare provider before starting or continuing treatment with Cosentyx.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067229/
[3] https://www.sciencedirect.com/science/article/pii/S2352647516300375